This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giles, F. J. Articles by Estey, E. H. Search for Related Content PubMed PubMed Citation Articles by Giles, F. J. Articles by Estey, E. H.

Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia

From the Department of Leukemia and the Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Francis J. Giles, MD, Department of Leukemia, Box 428, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; email: frankgiles{at}aol.com.

Purpose: Troxacitabine has activity in refractory myeloid leukemia, either as a single agent or when combined with cytarabine (ara-C) or with idarubicin. A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy.

Patients and Methods: Patients were randomized to receive idarubicin and ara-C (IA) versus troxacitabine and ara-C (TA) versus troxacitabine and idarubicin (TI). A Bayesian design was used to adaptively randomly assign patients to treatment. Thus, although there was initially an equal chance for randomization to IA, TA, or TI, treatment arms with a higher success rate progressively received a greater proportion of patients.

Results: Thirty-four patients were treated. Randomization to TI stopped after five patients and randomization to TA stopped after 11 patients. Defining success as complete remission (CR) that occurred within 49 days of starting treatment, success rates were 55% (10 of 18 patients) with IA, 27% (three of 11 patients) with TA, and 0% (zero of five patients) with TI. Because three CRs occurred after day 49, final CR rates were 55% (10 of 18 patients) with IA, 45% (five of 11 patients) with TA, and 20% (one of five patients) with TI. The probability that TA was inferior to IA was 70%, with a 5% probability that TA would have a 20% higher CR rate than IA. Survival was equivalent with all three regimens.

Conclusion: Neither troxacitabine combination was superior to IA in elderly patients with previously untreated adverse karyotype AML.

This article has been cited by other articles:

				A. Maloney, M. O. Karlsson, and U. S. H. Simonsson Optimal Adaptive Design in Clinical Drug Development: A Simulation Example J. Clin. Pharmacol., October 1, 2007; 47(10): 1231 - 1243. [Abstract] [Full Text] [PDF]

				R. G. Maki, J. K. Wathen, S. R. Patel, D. A. Priebat, S. H. Okuno, B. Samuels, M. Fanucchi, D. C. Harmon, S. M. Schuetze, D. Reinke, et al. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 J. Clin. Oncol., July 1, 2007; 25(19): 2755 - 2763. [Abstract] [Full Text] [PDF]

				G. J. Roboz, F. J. Giles, E. K. Ritchie, S. Allen-Bard, T. J. Curcio, M. A. Wilkes, S. L. Park, H. M. Kantarjian, S. Faderl, F. Ravandi, et al. Phase I/II Study of Continuous-Infusion Troxacitabine in Refractory Acute Myeloid Leukemia J. Clin. Oncol., January 1, 2007; 25(1): 10 - 15. [Abstract] [Full Text] [PDF]

				F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al. Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31. [Abstract] [Full Text] [PDF]

				D. A Berry Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis Clinical Trials, August 1, 2005; 2(4): 295 - 300. [Abstract] [PDF]

				M. Krams, K. R. Lees, and D. A. Berry The Past Is the Future: Innovative Designs in Acute Stroke Therapy Trials Stroke, June 1, 2005; 36(6): 1341 - 1347. [Full Text] [PDF]

				D. Rosenblum and S. Hirschfeld Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 3128 - 3128. [Abstract]